Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy

Condition(s) studied

Investigational drug(s) / intervention(s)

Neoadjuvant immunotherapy: Immune checkpoint inhibitors are used as neoadjuvant settings for NSCLC patients.

Other drugs for neoadjuvant treatment: Drugs other than immune checkpoint inhibitors are being used as a new adjuvant setting for patients with NSCLC.

Study summary

The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of different neoadjuvant immunotherapies in non-small cell lung cancer (NSCLC) patients using the real-world data. The main questions it aims to answer are:

* What the best setting for immune checkpoint inhibitors as the neoadjuvant treatment?
* How to determine the subgroups of patients benefit from neoadjuvant immunotherapy? Participants will receive neoadjuvant immunotherapy the study will analyze the real-world data.

Eligibility

Primary outcome measure(s)

• Pathological Complete Response (pCR) — Within 15 days after surgery
  defined as 0% of viable tumor cells in primary tumor and lymph nodes
• Disease-free survival (DFS) — DFS was defined as the time from surgery to the date of disease recurrence or death (by any cause in the absence of recurrence), up to about 10 years.
  Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).

Trial sites (1)

More Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials in China

Other trials for the same condition